ANI Pharmaceuticals, Inc. (ANIP)
USD 65.32
(-3.27%)
USD 65.32
(-3.27%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 904.42 Million USD | 18.99% |
| 2022 | 760.08 Million USD | -1.49% |
| 2021 | 771.59 Million USD | 67.31% |
| 2020 | 461.19 Million USD | 0.96% |
| 2019 | 456.78 Million USD | 6.08% |
| 2018 | 430.6 Million USD | 4.48% |
| 2017 | 412.13 Million USD | 27.65% |
| 2016 | 322.86 Million USD | 13.18% |
| 2015 | 285.26 Million USD | 8.17% |
| 2014 | 263.7 Million USD | 492.6% |
| 2013 | 44.5 Million USD | 14.78% |
| 2012 | 38.76 Million USD | -37.85% |
| 2011 | 62.37 Million USD | 39.34% |
| 2010 | 44.76 Million USD | 22.86% |
| 2009 | 36.43 Million USD | 106.1% |
| 2008 | 17.67 Million USD | -43.41% |
| 2007 | 31.24 Million USD | 39.65% |
| 2006 | 22.37 Million USD | 133.65% |
| 2005 | 9.57 Million USD | -46.29% |
| 2004 | 17.82 Million USD | 86.37% |
| 2003 | 9.56 Million USD | 62.68% |
| 2002 | 5.87 Million USD | 18.09% |
| 2001 | 4.97 Million USD | 62.35% |
| 2000 | 3.06 Million USD | -46.94% |
| 1999 | 5.77 Million USD | 67.56% |
| 1998 | 3.44 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 920.75 Million USD | 0.68% |
| 2024 Q1 | 914.52 Million USD | 1.12% |
| 2023 Q4 | 904.42 Million USD | 1.63% |
| 2023 Q3 | 889.91 Million USD | 3.56% |
| 2023 FY | 904.42 Million USD | 18.99% |
| 2023 Q1 | 765.22 Million USD | 0.68% |
| 2023 Q2 | 859.34 Million USD | 12.3% |
| 2022 Q3 | 739.11 Million USD | -1.63% |
| 2022 FY | 760.08 Million USD | -1.49% |
| 2022 Q1 | 744.84 Million USD | -3.47% |
| 2022 Q2 | 751.33 Million USD | 0.87% |
| 2022 Q4 | 760.08 Million USD | 2.84% |
| 2021 Q4 | 771.59 Million USD | 64.01% |
| 2021 FY | 771.59 Million USD | 67.31% |
| 2021 Q3 | 470.45 Million USD | -2.02% |
| 2021 Q2 | 480.15 Million USD | 3.52% |
| 2021 Q1 | 463.84 Million USD | 0.58% |
| 2020 Q2 | 465.39 Million USD | -3.49% |
| 2020 Q4 | 461.19 Million USD | -0.3% |
| 2020 Q3 | 462.58 Million USD | -0.6% |
| 2020 FY | 461.19 Million USD | 0.96% |
| 2020 Q1 | 482.23 Million USD | 5.57% |
| 2019 Q4 | 456.78 Million USD | 0.0% |
| 2019 FY | 456.78 Million USD | 6.08% |
| 2019 Q2 | 446.9 Million USD | 2.88% |
| 2019 Q1 | 434.39 Million USD | 0.88% |
| 2019 Q3 | 456.77 Million USD | 2.21% |
| 2018 Q2 | 424.17 Million USD | 1.47% |
| 2018 FY | 430.6 Million USD | 4.48% |
| 2018 Q4 | 430.6 Million USD | -2.01% |
| 2018 Q3 | 439.44 Million USD | 3.6% |
| 2018 Q1 | 418.01 Million USD | 1.43% |
| 2017 FY | 412.13 Million USD | 27.65% |
| 2017 Q4 | 412.13 Million USD | 11.25% |
| 2017 Q3 | 370.46 Million USD | 3.13% |
| 2017 Q2 | 359.21 Million USD | 0.58% |
| 2017 Q1 | 357.13 Million USD | 10.62% |
| 2016 Q4 | 322.86 Million USD | 1.09% |
| 2016 Q2 | 307.99 Million USD | 5.63% |
| 2016 FY | 322.86 Million USD | 13.18% |
| 2016 Q1 | 291.58 Million USD | 2.22% |
| 2016 Q3 | 319.37 Million USD | 3.69% |
| 2015 FY | 285.26 Million USD | 8.17% |
| 2015 Q1 | 265.98 Million USD | 0.86% |
| 2015 Q4 | 285.26 Million USD | 0.7% |
| 2015 Q3 | 283.27 Million USD | 4.87% |
| 2015 Q2 | 270.12 Million USD | 1.55% |
| 2014 Q2 | 95.42 Million USD | -1.27% |
| 2014 Q4 | 263.7 Million USD | 145.0% |
| 2014 Q3 | 107.63 Million USD | 12.8% |
| 2014 Q1 | 96.65 Million USD | 117.2% |
| 2014 FY | 263.7 Million USD | 492.6% |
| 2013 Q3 | 43.28 Million USD | 3.91% |
| 2013 Q1 | 35.35 Million USD | -8.8% |
| 2013 Q4 | 44.5 Million USD | 2.81% |
| 2013 FY | 44.5 Million USD | 14.78% |
| 2013 Q2 | 41.65 Million USD | 17.82% |
| 2012 Q4 | 38.76 Million USD | -10.28% |
| 2012 Q1 | 54.57 Million USD | -12.51% |
| 2012 FY | 38.76 Million USD | -37.85% |
| 2012 Q2 | 47.29 Million USD | -13.34% |
| 2012 Q3 | 43.21 Million USD | -8.63% |
| 2011 FY | 62.37 Million USD | 39.34% |
| 2011 Q4 | 62.37 Million USD | -16.71% |
| 2011 Q3 | 74.89 Million USD | 75.13% |
| 2011 Q2 | 42.76 Million USD | -24.72% |
| 2011 Q1 | 56.8 Million USD | 26.89% |
| 2010 Q3 | 40.76 Million USD | -21.28% |
| 2010 Q1 | 47.31 Million USD | 29.86% |
| 2010 FY | 44.76 Million USD | 22.86% |
| 2010 Q2 | 51.78 Million USD | 9.44% |
| 2010 Q4 | 44.76 Million USD | 9.82% |
| 2009 FY | 36.43 Million USD | 106.1% |
| 2009 Q1 | 13.21 Million USD | -25.25% |
| 2009 Q2 | 9.52 Million USD | -27.89% |
| 2009 Q3 | 15.95 Million USD | 67.47% |
| 2009 Q4 | 36.43 Million USD | 128.32% |
| 2008 Q4 | 17.67 Million USD | -10.81% |
| 2008 Q3 | 19.82 Million USD | -18.53% |
| 2008 Q2 | 24.32 Million USD | -15.28% |
| 2008 FY | 17.67 Million USD | -43.41% |
| 2008 Q1 | 28.71 Million USD | -8.08% |
| 2007 Q2 | 35.15 Million USD | 84.56% |
| 2007 Q4 | 31.24 Million USD | -6.51% |
| 2007 FY | 31.24 Million USD | 39.65% |
| 2007 Q1 | 19.04 Million USD | -14.85% |
| 2007 Q3 | 33.41 Million USD | -4.95% |
| 2006 FY | 22.37 Million USD | 133.65% |
| 2006 Q4 | 22.37 Million USD | 108.39% |
| 2006 Q3 | 10.73 Million USD | 118.94% |
| 2006 Q2 | 4.9 Million USD | -34.48% |
| 2006 Q1 | 7.48 Million USD | -21.84% |
| 2005 Q4 | 9.57 Million USD | -11.21% |
| 2005 Q1 | 15.2 Million USD | -14.71% |
| 2005 Q2 | 12.49 Million USD | -17.84% |
| 2005 FY | 9.57 Million USD | -46.29% |
| 2005 Q3 | 10.78 Million USD | -13.68% |
| 2004 FY | 17.82 Million USD | 86.37% |
| 2004 Q4 | 17.82 Million USD | -15.39% |
| 2004 Q1 | 8.67 Million USD | -9.35% |
| 2004 Q3 | 21.06 Million USD | -9.76% |
| 2004 Q2 | 23.34 Million USD | 169.28% |
| 2003 Q1 | 3.93 Million USD | -33.1% |
| 2003 FY | 9.56 Million USD | 62.68% |
| 2003 Q3 | 10.89 Million USD | 297.76% |
| 2003 Q4 | 9.56 Million USD | -12.22% |
| 2003 Q2 | 2.73 Million USD | -30.35% |
| 2002 Q3 | 5.78 Million USD | 169.86% |
| 2002 Q2 | 2.14 Million USD | -40.91% |
| 2002 FY | 5.87 Million USD | 18.09% |
| 2002 Q1 | 3.62 Million USD | -27.19% |
| 2002 Q4 | 5.87 Million USD | 1.71% |
| 2001 Q2 | 5.21 Million USD | -7.58% |
| 2001 Q3 | 6.49 Million USD | 24.58% |
| 2001 Q4 | 4.97 Million USD | -23.29% |
| 2001 FY | 4.97 Million USD | 62.35% |
| 2001 Q1 | 5.63 Million USD | 83.81% |
| 2000 Q3 | 3.72 Million USD | -2.76% |
| 2000 FY | 3.06 Million USD | -46.94% |
| 2000 Q1 | 5.29 Million USD | 0.0% |
| 2000 Q2 | 3.83 Million USD | -27.61% |
| 2000 Q4 | 3.06 Million USD | -17.67% |
| 1999 FY | 5.77 Million USD | 67.56% |
| 1998 FY | 3.44 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cosmos Health Inc. | 66.29 Million USD | -1264.227% |
| Safety Shot Inc | 12.7 Million USD | -7016.289% |
| Bright Green Corporation | 17.4 Million USD | -5096.918% |
| Embecta Corp. | 1.21 Billion USD | 25.525% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -1475.154% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 20.894% |
| Dynavax Technologies Corporation | 997.09 Million USD | 9.294% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -339.475% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -24.183% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 42.554% |
| PainReform Ltd. | 9.93 Million USD | -9007.976% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -3207.212% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -3207.212% |
| SCYNEXIS, Inc. | 128.41 Million USD | -604.313% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -3810.666% |
| Journey Medical Corporation | 76.84 Million USD | -1076.882% |
| Alpha Teknova, Inc. | 128.58 Million USD | -603.354% |
| Procaps Group, S.A. | 460.18 Million USD | -96.534% |
| Theratechnologies Inc. | 77.76 Million USD | -1062.96% |
| Harrow Health, Inc. | 311.75 Million USD | -190.107% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -5972.799% |
| Biofrontera Inc. | 27.93 Million USD | -3137.942% |
| DURECT Corporation | 45.18 Million USD | -1901.421% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 35.81% |
| Cronos Group Inc. | 1.13 Billion USD | 20.263% |
| OptiNose, Inc. | 107.72 Million USD | -739.534% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -91.992% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1516.511% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -3824.227% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -96.603% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -7488.593% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -1005.974% |
| Radius Health, Inc. | 1.71 Billion USD | 47.293% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -1597.265% |
| ProPhase Labs, Inc. | 91.92 Million USD | -883.848% |
| Phibro Animal Health Corporation | 982.18 Million USD | 7.917% |
| Procaps Group S.A. | 460.18 Million USD | -96.534% |
| Alvotech | 950.09 Million USD | 4.807% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -1988.3% |
| Viatris Inc. | 47.68 Billion USD | 98.103% |
| Rockwell Medical, Inc. | 52.17 Million USD | -1633.506% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -665.843% |
| SIGA Technologies, Inc. | 254.83 Million USD | -254.903% |
| Tilray Brands, Inc. | 4.33 Billion USD | 79.138% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -230.44% |
| Shineco, Inc. | 84.17 Million USD | -974.399% |
| PetIQ, Inc. | 868.22 Million USD | -4.169% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -10618.172% |
| Incannex Healthcare Limited | 17.04 Million USD | -5205.461% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 72.184% |
| Alimera Sciences, Inc. | 153.52 Million USD | -489.108% |
| Silver Spike Investment Corp. | 88.57 Million USD | -921.066% |
| Assertio Holdings, Inc. | 286.41 Million USD | -215.769% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -15095.936% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -2576.138% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -2794.799% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -6727.095% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -246.355% |
| Hempacco Co., Inc. | 18.04 Million USD | -4912.57% |
| Talphera, Inc. | 20.39 Million USD | -4334.528% |
| Alvotech | 950.09 Million USD | 4.807% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -122.676% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 45.225% |
| Currenc Group, Inc. | 141.49 Million USD | -539.211% |
| Kamada Ltd. | 351.96 Million USD | -156.96% |
| Indivior PLC | 1.95 Billion USD | 53.649% |
| Evoke Pharma, Inc. | 7.06 Million USD | -12695.022% |
| Flora Growth Corp. | 23.62 Million USD | -3728.079% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -6727.095% |
| Evolus, Inc. | 188.99 Million USD | -378.535% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 29.329% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 40.22% |
| Akanda Corp. | 8.83 Million USD | -10131.026% |